CI

At a glance

ClinicalIndex Comparison Record
N/ARecruiting· 590 target
Drug / intervention
Chemoradiation therapy +3 morecombination
Likely dose
Not stated in record
Key inclusion· 4
  • Total abdominal or laparoscopic hysterectomy with bilateral salpingectomy, pelvic lymphadenectomy or sentinel lymph node mapping and dissection
  • Histologically confirmed endometrioid type endometrial carcinoma, FIGO 2009 stage I with grade 3 (IA), grade 1-2 (IB), grade 3 (IB), or stage II
  • WHO performance status 0-2
  • Written informed consent
Key exclusion· 7
  • Residual disease
  • Other stage and type of endometrial carcinoma
  • Serous carcinoma, clear cell carcinoma (≥10% if mixed), undifferentiated or neuroendocrine carcinoma
  • Uterine sarcoma including carcinosarcoma

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05179447
NCT05179447N/ARecruitingOn TrackUpdated 15mo ago
Long Recruiting

Randomized Phase III Trial of Molecular Profile-based Versus Standard Recommendations for Adjuvant Therapy for Women With Early Stage Endometrioid Adenocarcinoma

Women's Hospital School Of Medicine Zhejiang University·interventional·Posted Jan 5, 2022·Updated Apr 1, 2025

In Brief

A clinical study evaluating Vaginal brachytherapy, External beam radiotherapy, and 2 other interventions for Endometrial Cancer Stage I and Endometrial Cancer Stage II. Currently recruiting, targeting 590 participants across 10 sites.

Detailed Summary

This is a prospective, multicenter, randomized phase III trial among women with endometrioid adenocarcinoma with high-intermediate and intermediate risk features to investigate the role of integrated genomic-pathologic classification to determine if participants should receive no adjuvant therapy, vaginal brachytherapy, external beam radiotherapy or chemo-radiation therapy based on molecular features as compared to standard radiation therapy.

Study Details

Timeline

N/ARecruiting
202220232024202520262027
First PostedJan 5, 2022
Enrollment StartJan 24, 2022
Primary CompletionDec 31, 2026
Study CompletionJan 1, 2027
TodayJul 2, 2026
Enrollment to primary: 4.9 yearsPosted 4.5 years agoPrimary completion in 6 months

Interventions

Vaginal brachytherapyradiation

Internal radiation of the vaginal vault using a vaginal cylinder. For brachytherapy administered alone it is recommended: suggested dose is either 3 fractions of 7 Gy or 5 fractions of 6 Gy. For brachytherapy administered after completion of External beam radiotherapy (EBRT): Total dose should aim to be 65 Gy, and suggested dose is 2-3 fractions of 5-6 Gy

External beam radiotherapyradiation

External beam pelvic radiotherapy on a linear accelerator, 45-50 Gy in 25-28 out-patients sessions

Observationother

No adjuvant therapy, but active follow-up and quality of life questionnaires as in the groups who have adjuvant treatment

Chemoradiation therapycombination

4 adjuvant cycles carboplatin and paclitaxel followed by External beam pelvic radiotherapy (45-50 Gy )